Percentage of hepatitis after halothane use
**Core Concept**
Halothane is a potent inhalational anesthetic agent that has been associated with a rare but serious side effect: hepatitis. This condition is known as halothane hepatitis, and it is characterized by an immune-mediated reaction to the metabolism of halothane in the liver. The exact mechanism is not fully understood, but it is thought to involve the formation of reactive metabolites that trigger an immune response.
**Why the Correct Answer is Right**
Halothane is metabolized in the liver by cytochrome P450 enzymes, which convert it into a variety of reactive metabolites. Some of these metabolites can covalently bind to liver proteins, leading to an immune response and the release of pro-inflammatory cytokines. This can result in liver damage and inflammation, characteristic of hepatitis. The incidence of halothane hepatitis is estimated to be around 1 in 35,000 to 1 in 40,000 patients.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not accurately reflect the known incidence of halothane hepatitis.
**Option B:** This option is incorrect because it suggests a different mechanism of action for halothane, which is not supported by the current understanding of its metabolism and toxicity.
**Option C:** This option is incorrect because it implies a higher incidence of halothane hepatitis than is actually reported in the literature.
**Clinical Pearl / High-Yield Fact**
Halothane hepatitis is a rare but serious side effect of halothane anesthesia, and it is thought to be related to the formation of reactive metabolites during its metabolism in the liver. This condition is more likely to occur in patients who have been exposed to multiple anesthetic agents, particularly those that are metabolized by the same cytochrome P450 enzymes.
**Correct Answer:** 1 in 35,000 to 1 in 40,000